| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
FP Receptor ~30 nM (Ki) PGF2α
PDC31 specifically targets the FP Prostaglandin Receptor. Unlike competitive antagonists that bind the active site, PDC31 binds to an allosteric site on the receptor, leading to a conformational change that inhibits receptor function. It also enhances Ca2+-dependent large-conductance K+ channels in human myometrial cells. |
|---|---|
| ln Vitro |
In human myometrial smooth muscle cells, PDC31 (10 μM, 50 μM) activates BKCa channels and increases open-state channel activity by an average of 4- and 6-fold at 10 μM and 50 μM, respectively [2]. PDC31 cumulatively suppresses the spontaneous contractions of human myometrium in vitro at intervals of 20 minutes (1 nM–10 μM) [2]. The ILGHXDYK sequence, which is present in the transmembrane domain of the human PGF2a receptor, makes up PDC31 [3]. PDC31 can delay birth in preterm animal models and lessen the length and force of PGF2a-induced contractions in the muscle strip model [4].
In vitro, PDC31 (50 microM) stimulates the BKCa channel in human myometrial smooth muscle cells, increasing open-state channel activity by 4-fold at 10 microM and 6-fold at 50 microM. Furthermore, PDC31 (1 nM - 10 microM) administered at 20-minute intervals cumulatively inhibits spontaneous contractions in isolated pregnant human myometrium. |
| ln Vivo |
In in vivo studies, PDC31 effectively decreases the strength and duration of uterine contractions. This biological activity makes it a promising candidate for research applications focused on tocolysis, specifically the pharmacological inhibition of premature uterine contractions to delay preterm birth.
|
| Enzyme Assay |
The specific in vitro receptor binding protocol for PDC31 may utilize surface plasmon resonance (SPR) or radioligand binding assays to evaluate its interaction with the FP receptor. In a functional assay, cells expressing the FP receptor are pre-incubated with varying concentrations of PDC31, followed by stimulation with a fixed concentration of the FP agonist PGF2alpha. The inhibitory effect of PDC31 on PGF2alpha-induced calcium mobilization or inositol phosphate accumulation is then measured to confirm its non-competitive antagonism.
|
| Cell Assay |
In a standard in vitro cell-based assay, human myometrial smooth muscle cells or cell lines (e.g., PHM1-41) are cultured in standard medium. After reaching confluence, cells are incubated with increasing concentrations of PDC31 (1 nM, 10 nM, 100 nM, 1 uM, 10 uM). The contractility of the cells is assessed using a collagen gel contraction assay or by measuring intracellular calcium flux using fluorescent calcium indicators (e.g., Fura-2 AM). This setup allows for the quantification of the peptide's inhibitory effects on cell contraction.
|
| Animal Protocol |
A standard in vivo protocol for assessing tocolytic activity uses pregnant rodents, typically at gestational day 18-19 (near term). Under anesthesia, uterine contractility is monitored via an intrauterine pressure catheter. PDC31 is administered intravenously or intraperitoneally at doses ranging from 0.1 to 10 mg/kg. The primary endpoint is the reduction in frequency, amplitude, and duration of uterine contractions post-administration. Control groups receive a vehicle control or a known tocolytic agent. Maternal safety and fetal viability are also monitored as secondary endpoints.
|
| ADME/Pharmacokinetics |
As a peptide compound, PDC31 is expected to have low oral bioavailability and a relatively short plasma half-life due to protease degradation. When administered systemically, it is likely to be rapidly cleared through renal excretion and metabolic degradation. Detailed pharmacokinetic parameters (e.g., Cmax, T1/2, AUC) for this specific compound are not available in standard databases.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicity data for PDC31 is limited to preclinical observations. As a non-competitive FP receptor antagonist, it is designed to minimize off-target hormonal effects. Potential toxicities may include hypotension due to smooth muscle relaxation or off-target effects on other prostanoid receptors at high concentrations. Systemic toxicity assessments would typically evaluate liver and kidney function markers, as well as histopathological changes in major organs following repeated dosing in animal models.
|
| References |
|
| Additional Infomation |
PDC31 is exclusively a research chemical and has not yet received regulatory approval for clinical use. Its unique mechanism of action as an allosteric inhibitor provides a novel approach to tocolysis by modulating the FP receptor. The peptide consists of D-amino acids, which enhances its resistance to enzymatic degradation and improves metabolic stability compared to L-peptides. This structural feature is crucial for its potential in vivo efficacy.
|
| Molecular Formula |
C45H71N13O13
|
|---|---|
| Molecular Weight |
1002.12455010414
|
| Exact Mass |
1001.529
|
| CAS # |
634586-40-6
|
| PubChem CID |
57392015
|
| Appearance |
White to off-white solid powder
|
| LogP |
-5.8
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
33
|
| Heavy Atom Count |
71
|
| Complexity |
1780
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C(O)(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@@H](CC1N=CNC=1)NC(=O)CNC(=O)[C@@H](CC(C)C)NC(=O)[C@@H]([C@H](C)CC)N
|
| InChi Key |
IVQBXMPXSLAIFC-OSMHAOILSA-N
|
| InChi Code |
InChI=1S/C45H71N13O13/c1-5-25(4)37(47)43(68)58-31(17-24(2)3)38(63)51-22-35(60)53-33(19-27-21-49-23-52-27)41(66)54-29(10-8-16-50-45(48)71)39(64)57-34(20-36(61)62)42(67)56-32(18-26-11-13-28(59)14-12-26)40(65)55-30(44(69)70)9-6-7-15-46/h11-14,21,23-25,29-34,37,59H,5-10,15-20,22,46-47H2,1-4H3,(H,49,52)(H,51,63)(H,53,60)(H,54,66)(H,55,65)(H,56,67)(H,57,64)(H,58,68)(H,61,62)(H,69,70)(H3,48,50,71)/t25-,29-,30-,31-,32-,33-,34-,37-/m1/s1
|
| Chemical Name |
(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-[[2-[[(2R)-2-[[(2R,3R)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (99.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9979 mL | 4.9894 mL | 9.9787 mL | |
| 5 mM | 0.1996 mL | 0.9979 mL | 1.9957 mL | |
| 10 mM | 0.0998 mL | 0.4989 mL | 0.9979 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT01250587
Conditions:DysmenorrheaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
